Molecular and Genetic Medicine

Expanding KRAS Gene Testing: We’re Ready and Here’s Why

Abstract

Cinthya Sternberg*, Mariana Macedo, Dirce Maria Carraro, Stephen Stefani, Marcos Santos and Isabela Werneck Da Cunha

Purpose: The aim of this review was to address the barriers limiting access to the use of molecular diagnostics, specifically KRAS testing for cancers with potential to benefit from targeted drugs in Brazil. A panel reviewed examples from current state and potential future uses of KRAS testing in cancer diagnosis and treatment designation.

Design: A selected panel of Brazilian experts in fields related to KRAS testing were provided with a series of relevant questions to address prior to the multi-day conference. Within this meeting, each narrative was discussed and edited by the entire group, through several drafts and rounds of discussion until a consensus was achieved.

Results: The authors propose specific and actionable recommendations for expanding access to KRAS testing use in cancer care in Brazil and in other countries, in a similar situation. In creating these recommendations, the authors strived to address all barriers and impediments mentioned previously within this review.

Conclusion: Given the current benefits and likely future applications, there is a great need to expand molecular testing and KRAS testing in Brazil, and adapting the current framework is essential to accomplishing this goal. Regulatory actions and increased knowledge and awareness to expand access to this technology have the potential to improve cancer patient care across the country. Therefore, the recommendations in this review can serve as an outline for technology adoption in Brazil and other countries with similar challenges in optimizing cancer care.